Merck KGaA drafts in FD to handle Schering bid

DARMSTADT: Merck KGaA has brought in Financial Dynamics’ German joint venture firm A&B FD as it makes an unusual hostile bid for contraceptive pill inventor Schering.

Merck, the German drug company behind colorectal cancer drug Erbitux, announced its €14.6bn (£10.1bn) bid for Schering on Monday, a day after Schering said Merck had made the €77-
a-share cash offer.

Brunswick is handling financial comms for Schering around the bid.
A merger of the German firms would create a company with a global lead in the market for birth control pills and a range of drugs to treat multiple sclerosis and cancer. The two German companies bear no relation to US groups Merck and Schering-Plough.

Although Merck's offer represented a 15.4 per cent premium on Schering's share price, Schering's board rejected it, claiming the bid undervalued the company.

Cost cutting has helped Schering to beat analyst expectations with a 21 per cent rise in operating profit to £638m in 2005.

Schering is thought to be holding out for a 35 per cent premium, which would value the company at €17.1bn.

Hostile bids of this nature are rare in Germany. But the fact that 70
per cent of Schering is owned by different market players has made it an attractive target.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in